nach oben

International Urology and Nephrology

Erschienen in:

08.03.2021 | Nephrology - Review

The role of Elabela in kidney disease

verfasst von: Qian Zheng, Geng Tian, Feng Xu, Xin Ci, Rumei Luan, Linlin Wu, Xuehong Lu

Erschienen in: International Urology and Nephrology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Elabela, also known as Toddler or Apela, is a recently discovered hormonal peptide containing 32 amino acids. Elabela is a ligand of the apelin receptor (APJ). APJ is a G protein-coupled receptor widely expressed throughout body, and together with its cognate ligand, apelin, it plays an important role in various physiological processes including cardiovascular functions, angiogenesis and fluid homeostasis. Elabela also participates in embryonic development and pathophysiological processes in adulthood. Elabela is highly expressed in undifferentiated embryonic stem cells and regulates endoderm differentiation and cardiovascular system development. During differentiation, Elabela is highly expressed in pluripotent stem cells and in adult renal collecting ducts and loops, where it functions to maintain water and sodium homeostasis. Other studies have also shown that Elabela plays a crucial role in the pathogenesis of kidney diseases. This review addresses the role of Elabela in kidney diseases including renal ischemia/reperfusion injury, hypertensive nephropathy, diabetic nephropathy, and cardiorenal syndrome.

Yu XH et al (2014) Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta 428:1–8PubMedCrossRef

Hwangbo C et al (2017) Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin’s glucose-lowering effects. Sci Transl Med 9(407):eaad4000PubMedPubMedCentralCrossRef

Lv D et al (2016) PAK1-cofilin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13. Clin Exp Pharmacol Physiol 43(5):569–579PubMedCrossRef

Wu L, Chen L, Li L (2017) Apelin/APJ system: a novel promising therapy target for pathological angiogenesis. Clin Chim Acta 466:78–84PubMedCrossRef

Pauli A et al (2014) Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science 343(6172):1248636PubMedPubMedCentralCrossRef

Chng SC et al (2013) ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell 27(6):672–680PubMedCrossRef

Reichman-Fried M, Raz E (2014) Small proteins, big roles: the signaling protein Apela extends the complexity of developmental pathways in the early zebrafish embryo. BioEssays 36(8):741–745PubMedCrossRef

Ho L et al (2015) ELABELA is an endogenous growth factor that sustains hESC self-renewal via the PI3K/AKT pathway. Cell Stem Cell 17(4):435–447PubMedCrossRef

Wang Z et al (2015) Elabela-apelin receptor signaling pathway is functional in mammalian systems. Sci Rep 5:8170PubMedPubMedCentralCrossRef

10.

Deng C et al (2015) Apela regulates fluid homeostasis by binding to the APJ receptor to activate Gi signaling. J Biol Chem 290(30):18261–18268PubMedPubMedCentralCrossRef

11.

O’Carroll AM et al (2017) Expression and functional implications of the renal apelinergic system in rodents. PLoS ONE 12(8):e0183094PubMedPubMedCentralCrossRef

12.

Xu J et al (2018) Biological functions of Elabela, a novel endogenous ligand of APJ receptor. J Cell Physiol 233(9):6472–6482PubMedCrossRef

13.

Chen H et al (2017) ELABELA and an ELABELA fragment protect against AKI. J Am Soc Nephrol 28(9):2694–2707PubMedPubMedCentralCrossRef

14.

O’Dowd BF et al (1993) A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136(1–2):355–360PubMedCrossRef

15.

Tatemoto K et al (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251(2):471–476PubMedCrossRef

16.

Hu H et al (2016) Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab 119(1–2):20–27PubMedCrossRef

17.

Kuba K et al (2019) Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology. Peptides 111:62–70PubMedCrossRef

18.

Sato T et al (2013) Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest 123(12):5203–5211PubMedPubMedCentralCrossRef

19.

Goidescu CM, Vida-Simiti LA (2015) The apelin-APJ system in the evolution of heart failure. Clujul Med 88(1):3–8PubMedPubMedCentral

20.

Tycinska AM et al (2012) Apelin in acute myocardial infarction and heart failure induced by ischemia. Clin Chim Acta 413(3–4):406–410PubMedCrossRef

21.

Barnes G, Japp AG, Newby DE (2010) Translational promise of the apelin-APJ system. Heart 96(13):1011–1016PubMedCrossRef

22.

Wysocka MB, Pietraszek-Gremplewicz K, Nowak D (2018) The role of apelin in cardiovascular diseases. Obesity Cancer Front Physiol 9:557PubMedCrossRef

23.

Adam F et al (2016) Apelin: an antithrombotic factor that inhibits platelet function. Blood 127(7):908–920PubMedCrossRef

24.

Sabry MM et al (2019) Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats. Arch Physiol Biochem 125(3):244–254PubMedCrossRef

25.

Huang Z, Wu L, Chen L (2018) Apelin/APJ system: a novel potential therapy target for kidney disease. J Cell Physiol 233(5):3892–3900PubMedCrossRef

26.

Najafipour H et al (2012) Apelin receptor expression in ischemic and non- ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats. Regul Pept 178(1–3):43–50PubMedCrossRef

27.

Flahault A et al (2017) Role of the vasopressin/apelin balance and potential use of metabolically stable apelin analogs in water metabolism disorders. Front Endocrinol (Lausanne) 8:120CrossRef

28.

Quertermous T (2007) Apelin and its g protein-coupled receptor regulate cardiac development as well as cardiac function. Dev Cell 12(3):319–320PubMedCrossRef

29.

Zeng XX et al (2007) Apelin and its receptor control heart field formation during zebrafish gastrulation. Dev Cell 12(3):391–402PubMedCrossRef

30.

Charo DN et al (2009) Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol 297(5):H1904–H1913PubMedPubMedCentralCrossRef

31.

Yang P, Maguire JJ, Davenport AP (2015) Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci 36(9):560–567PubMedPubMedCentralCrossRef

32.

Schreiber CA et al (2017) Sustained ELABELA gene therapy in high-salt diet-induced hypertensive rats. Curr Gene Ther 16(5):349–360PubMedCrossRef

33.

Li M et al (2015) An apela RNA-containing negative feedback loop regulates p53-mediated apoptosis in embryonic stem cells. Cell Stem Cell 16(6):669–683PubMedPubMedCentralCrossRef

34.

Miyazaki T et al (2019) Cell-specific image-guided transcriptomics identifies complex injuries caused by ischemic acute kidney injury in mice. Commun Biol 2:326PubMedPubMedCentralCrossRef

35.

Bonventre JV, Zuk A (2004) Ischemic acute renal failure: an inflammatory disease? Kidney Int 66(2):480–485PubMedCrossRef

36.

Nishikawa H et al (2018) Knockout of the interleukin-36 receptor protects against renal ischemia-reperfusion injury by reduction of proinflammatory cytokines. Kidney Int 93(3):599–614PubMedCrossRef

37.

Yoshida T et al (2012) Caspase-3-independent internucleosomal DNA fragmentation in ischemic acute kidney injury. Nephron Exp Nephrol 120(3):e103–e113PubMedCrossRef

38.

Ogbadu J, Singh G, Aggarwal D (2019) Factors affecting the transition of acute kidney injury to chronic kidney disease: potential mechanisms and future perspectives. Eur J Pharmacol 865:172711PubMedCrossRef

39.

Munoz-Felix JM et al (2015) TGF-beta/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations? Pharmacol Ther 156:44–58PubMedCrossRef

40.

Chen L et al (2018) Central role of dysregulation of TGF-beta/Smad in CKD progression and potential targets of its treatment. Biomed Pharmacother 101:670–681PubMedCrossRef

41.

Sedlakova L et al (2018) 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Biosci Rep 38(5):BSR20171496PubMedPubMedCentralCrossRef

42.

Shirai A et al (2014) Angiotensin II dose-dependently stimulates human renal proximal tubule transport by the nitric oxide/guanosine 3′,5′-cyclic monophosphate pathway. J Am Soc Nephrol 25(7):1523–1532PubMedPubMedCentralCrossRef

43.

Li Y et al (2019) Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function: a preliminary study. Clin Exp Hypertens 42(3):239–243PubMedCrossRef

44.

Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14(2):88–98PubMedCrossRef

45.

Zhang Y et al (2019) Elabela protects against podocyte injury in mice with streptozocin-induced diabetes by associating with the PI3K/Akt/mTOR pathway. Peptides 114:29–37PubMedCrossRef

46.

Wang G et al (2019) The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases. J Transl Med 17(1):264PubMedPubMedCentralCrossRef

47.

Demirpence M et al (2019) Apelin: a potential novel serum biomarker for early detection of diabetic nephropathy in patients with type 2 diabetes. North Clin Istanb 6(2):151–155PubMed

48.

Zhang H et al (2018) Serum Elabela/toddler levels are associated with albuminuria in patients with type 2 diabetes. Cell Physiol Biochem 48(3):1347–1354PubMedCrossRef

49.

Fu Q et al (2014) Cardiorenal syndrome: pathophysiological mechanism, preclinical models, novel contributors and potential therapies. Chin Med J (Engl) 127(16):3011–3018

50.

Marsault E et al (2019) The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. Ann N Y Acad Sci 1455(1):12–33PubMedPubMedCentralCrossRef

51.

Sato T et al (2017) ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage. Cardiovasc Res 113(7):760–769PubMedCrossRef

52.

Yang P et al (2017) Elabela/toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation 135(12):1160–1173PubMedPubMedCentralCrossRef

53.

Coquerel D et al (2017) ELABELA improves cardio-renal outcome in fatal experimental septic shock. Crit Care Med 45(11):e1139–e1148PubMedCrossRef

54.

Lu L et al (2017) Elabela, a new endogenous ligand of APJ, functions in embryos and adults organisms. Acta Biochim Biophys Sin (Shanghai) 49(4):378–381CrossRef

55.

Warren AY, Harrison D (2018) WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol 36(12):1913–1926PubMedPubMedCentralCrossRef

56.

Moch H et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 70(1):93–105PubMedCrossRef

57.

Williamson SR et al (2017) Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Hum Pathol 63:149–156PubMedCrossRef

58.

Cirone P et al (2014) Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol 73(3):525–538PubMedCrossRef

59.

Artas G et al (2019) A promising biomarker to distinguish benign and malignant renal tumors: ELABELA. Niger J Clin Pract 22(3):386–392PubMed

Titel: The role of Elabela in kidney disease
verfasst von: Qian Zheng
Geng Tian
Feng Xu
Xin Ci
Rumei Luan
Linlin Wu
Xuehong Lu
Publikationsdatum: 08.03.2021
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 9/2021
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-021-02790-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2021

Potassium citrate vs. hydrochlorothiazide to reduce urinary calcium excretion in calcium oxalate stone patients with hypercalciuria: a prospective randomized study

Perioperative outcomes of goal-directed versus conventional fluid therapy in radical cystectomy with enhanced recovery protocol

Urinary continence after high urogenital sinus repair conducted with posterior prone approach: electromyography-uroflowmetric assessment

Pilot health technology assessment study: organizational and economic impact of remote monitoring system for home automated peritoneal dialysis

Thyroid function in patients with idiopathic nephrotic syndrome